



<p>At Oxford Immunotec Ltd: Dr Peter Wrighton-Smith, CEO or Mr Ian Miscampbell, CFO</p> <p>Oxford Immunotec 91 Milton Park Abingdon Oxfordshire OX14 4RY, UK</p> <p>Tel: +44 (0)1235 442780 Fax: +44 (0)1235 442781 Email: info@oxfordimmunotec.com</p>	<p>At Northbank Communications: (for Oxford Immunotec)</p> <p>Lorna Watson, Account Manager Northbank Communications Ltd The Media Village, 131-151 Great Titchfield Street, London, W1W 5BB, UK</p> <p>Tel: +44 (0)20 7886 8156 Fax: +44 (0)20 7886 8151 Email: www.northbankcommunications.com</p>
--	--

Oxford Immunotec Wins Medical Futures Innovation Award

Oxford, UK; 4 November 2005 – Oxford Immunotec's revolutionary new blood test for diagnosing TB infection, called T-SPOT™.TB has won the Equinox-sponsored award for the Best Business Proposition at the Medical Futures Innovation Awards 2005.

The test is based on a breakthrough in diagnostic testing that allows the measurement of individual T cells specific to Mycobacterium tuberculosis. T-SPOT.TB was approved for sale in Europe last year. Until recently the only means of testing for TB infection was the 115 year old tuberculin skin test (TST). T-SPOT.TB is the only effective test for the reliable screening and early detection of latent TB infection in immuno-compromised patients and offers a substantially more accurate, effective and efficient tool for identifying and controlling the spread of TB.

The prestigious Medical Futures awards, which this year attracted a record 1,200 entries, were judged by a high-profile panel including Dame Carol Black, the President of the Royal College of Physicians, Professor Aidan Halligan, the NHS Director of Clinical Governance and Harry Cayton, the Department of Health Director of Patients and the Public.

Oxford Immunotec beat selected finalists including entries for a non-invasive fracture fixation system and a hand-held device to measure blood flow problems. The Company's success in winning the Best Business Proposition award underlines the market potential for T-SPOT.TB.

Commenting on the award Dr Peter Wrighton-Smith, Oxford Immunotec's Chief Executive Officer, said, "We are delighted that we have been selected to receive this prestigious award. As the threat of a TB epidemic looms, this award highlights the need to bring TB testing into the 21st century and is a validation of the commercial value of our revolutionary technology platform."

- ENDS -

Notes to editors:

Photographs available on request.

About Oxford Immunotec

www.oxfordimmunotec.com

Oxford Immunotec, the T-Cell measurement company, is headquartered near Oxford, UK. The Company develops and sells clinical diagnostic products based on its patented T-SPOT™ technology, the first regulatory approved method for directly quantifying antigen-specific T cells.

T-SPOT is a simple and extremely accurate method of studying a person's cellular immune response to infection and can be applied to diagnose and monitor any major disease driven by a T-Cell response.

About T-SPOT™. TB

T-SPOT. TB is an *in vitro* T-Cell measurement assay used for diagnosing TB infection and the first product from Oxford Immunotec using the T-SPOT™ technology. The product is extremely robust in that it gives a result every time and offers unrivalled and maintained sensitivity in high risk and immuno-compromised patient groups. T-SPOT. TB is approved for sale in Europe and is designed to replace the 115 year old tuberculin skin test. As such it offers a substantially more accurate and effective tool for controlling the spread of TB, addressing a market of £600m.

T-SPOT is a trademark of Oxford Immunotec.

About the Medical Futures Innovations Awards

The Awards, which were set up in 2001 by practicing NHS doctor, Dr Andy Goldberg, are designed to encourage and promote a culture of creativity, innovation and leadership amongst healthcare professionals and facilitate the successful commercialisation of these ideas.

This year the Medical Futures Innovations Awards attracted a record 1,200 entries. The winners, chosen by an illustrious panel of judges, which included Dame Carol Black, President, Royal College of Physicians; Professor Aidan Halligan, Director of Clinical Governance, NHS and Harry Cayton, Director, Patients and the Public, Department of Health, were announced on 3rd November 2005.